nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Vemurafenib—skin cancer	0.693	1	CiPCiCtD
Crizotinib—ABCB1—Vismodegib—skin cancer	0.00573	0.193	CbGbCtD
Crizotinib—CYP3A4—Imiquimod—skin cancer	0.00495	0.167	CbGbCtD
Crizotinib—CYP3A4—Temozolomide—skin cancer	0.00495	0.167	CbGbCtD
Crizotinib—CYP3A4—Vismodegib—skin cancer	0.00343	0.116	CbGbCtD
Crizotinib—ABCB1—Dactinomycin—skin cancer	0.00301	0.101	CbGbCtD
Crizotinib—CYP3A4—Vemurafenib—skin cancer	0.00271	0.0915	CbGbCtD
Crizotinib—CYP3A5—Docetaxel—skin cancer	0.00239	0.0805	CbGbCtD
Crizotinib—ABCB1—Docetaxel—skin cancer	0.00155	0.0524	CbGbCtD
Crizotinib—AURKA—Sorafenib—Vismodegib—skin cancer	0.00136	1	CbGdCrCtD
Crizotinib—CYP3A4—Docetaxel—skin cancer	0.000931	0.0314	CbGbCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000456	0.00554	CcSEcCtD
Crizotinib—Face oedema—Imiquimod—skin cancer	0.000455	0.00554	CcSEcCtD
Crizotinib—Weight decreased—Vemurafenib—skin cancer	0.000432	0.00526	CcSEcCtD
Crizotinib—Nervous system disorder—Vismodegib—skin cancer	0.000431	0.00525	CcSEcCtD
Crizotinib—Febrile neutropenia—Docetaxel—skin cancer	0.00043	0.00523	CcSEcCtD
Crizotinib—Skin disorder—Vismodegib—skin cancer	0.000427	0.0052	CcSEcCtD
Crizotinib—Infestation NOS—Vemurafenib—skin cancer	0.000426	0.00518	CcSEcCtD
Crizotinib—Infestation—Vemurafenib—skin cancer	0.000426	0.00518	CcSEcCtD
Crizotinib—Neuropathy peripheral—Vemurafenib—skin cancer	0.000418	0.00508	CcSEcCtD
Crizotinib—Gait disturbance—Temozolomide—skin cancer	0.000399	0.00485	CcSEcCtD
Crizotinib—Respiratory failure—Temozolomide—skin cancer	0.000397	0.00482	CcSEcCtD
Crizotinib—Pulmonary embolism—Temozolomide—skin cancer	0.000389	0.00473	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Temozolomide—skin cancer	0.000389	0.00473	CcSEcCtD
Crizotinib—Dyspepsia—Vismodegib—skin cancer	0.000387	0.00471	CcSEcCtD
Crizotinib—Decreased appetite—Vismodegib—skin cancer	0.000382	0.00465	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vismodegib—skin cancer	0.00038	0.00462	CcSEcCtD
Crizotinib—Fatigue—Vismodegib—skin cancer	0.000379	0.00461	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Imiquimod—skin cancer	0.000379	0.00461	CcSEcCtD
Crizotinib—Oedema peripheral—Vemurafenib—skin cancer	0.000377	0.00458	CcSEcCtD
Crizotinib—Haemoglobin decreased—Docetaxel—skin cancer	0.000376	0.00457	CcSEcCtD
Crizotinib—Constipation—Vismodegib—skin cancer	0.000376	0.00457	CcSEcCtD
Crizotinib—Sepsis—Dactinomycin—skin cancer	0.000374	0.00454	CcSEcCtD
Crizotinib—Neuralgia—Docetaxel—skin cancer	0.000373	0.00453	CcSEcCtD
Crizotinib—Burning sensation—Docetaxel—skin cancer	0.000373	0.00453	CcSEcCtD
Crizotinib—Interstitial lung disease—Docetaxel—skin cancer	0.000366	0.00445	CcSEcCtD
Crizotinib—Neuropathy—Temozolomide—skin cancer	0.000366	0.00445	CcSEcCtD
Crizotinib—Infestation NOS—Imiquimod—skin cancer	0.000363	0.00442	CcSEcCtD
Crizotinib—Infestation—Imiquimod—skin cancer	0.000363	0.00442	CcSEcCtD
Crizotinib—Eye disorder—Vemurafenib—skin cancer	0.000358	0.00435	CcSEcCtD
Crizotinib—Neuropathy peripheral—Imiquimod—skin cancer	0.000356	0.00433	CcSEcCtD
Crizotinib—Cardiac disorder—Vemurafenib—skin cancer	0.000355	0.00432	CcSEcCtD
Crizotinib—Hepatic failure—Dactinomycin—skin cancer	0.000348	0.00423	CcSEcCtD
Crizotinib—Mediastinal disorder—Vemurafenib—skin cancer	0.000345	0.00419	CcSEcCtD
Crizotinib—Hepatobiliary disease—Imiquimod—skin cancer	0.000344	0.00418	CcSEcCtD
Crizotinib—Photophobia—Fluorouracil—skin cancer	0.000337	0.0041	CcSEcCtD
Crizotinib—Hepatotoxicity—Docetaxel—skin cancer	0.000335	0.00408	CcSEcCtD
Crizotinib—Malnutrition—Vemurafenib—skin cancer	0.000333	0.00405	CcSEcCtD
Crizotinib—Dysgeusia—Vemurafenib—skin cancer	0.000326	0.00397	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.000325	0.00395	CcSEcCtD
Crizotinib—Urinary tract disorder—Imiquimod—skin cancer	0.000322	0.00392	CcSEcCtD
Crizotinib—Urethral disorder—Imiquimod—skin cancer	0.00032	0.00389	CcSEcCtD
Crizotinib—Asthenia—Vismodegib—skin cancer	0.000316	0.00384	CcSEcCtD
Crizotinib—Hepatic failure—Temozolomide—skin cancer	0.000315	0.00382	CcSEcCtD
Crizotinib—Visual impairment—Imiquimod—skin cancer	0.000314	0.00382	CcSEcCtD
Crizotinib—Sepsis—Fluorouracil—skin cancer	0.000311	0.00379	CcSEcCtD
Crizotinib—Eye disorder—Imiquimod—skin cancer	0.000305	0.00371	CcSEcCtD
Crizotinib—Diarrhoea—Vismodegib—skin cancer	0.000301	0.00366	CcSEcCtD
Crizotinib—Mediastinal disorder—Imiquimod—skin cancer	0.000294	0.00358	CcSEcCtD
Crizotinib—Arrhythmia—Imiquimod—skin cancer	0.000291	0.00354	CcSEcCtD
Crizotinib—Malnutrition—Imiquimod—skin cancer	0.000284	0.00345	CcSEcCtD
Crizotinib—Diplopia—Temozolomide—skin cancer	0.000283	0.00344	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000282	0.00342	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000281	0.00342	CcSEcCtD
Crizotinib—Vomiting—Vismodegib—skin cancer	0.00028	0.0034	CcSEcCtD
Crizotinib—Rash—Vismodegib—skin cancer	0.000277	0.00337	CcSEcCtD
Crizotinib—Dermatitis—Vismodegib—skin cancer	0.000277	0.00337	CcSEcCtD
Crizotinib—Face oedema—Temozolomide—skin cancer	0.000273	0.00332	CcSEcCtD
Crizotinib—Infection—Vemurafenib—skin cancer	0.00027	0.00328	CcSEcCtD
Crizotinib—Nervous system disorder—Vemurafenib—skin cancer	0.000267	0.00324	CcSEcCtD
Crizotinib—Skin disorder—Vemurafenib—skin cancer	0.000264	0.00321	CcSEcCtD
Crizotinib—Respiratory failure—Docetaxel—skin cancer	0.000264	0.00321	CcSEcCtD
Crizotinib—Weight decreased—Bleomycin—skin cancer	0.000262	0.00319	CcSEcCtD
Crizotinib—Nausea—Vismodegib—skin cancer	0.000261	0.00318	CcSEcCtD
Crizotinib—Pneumonia—Bleomycin—skin cancer	0.00026	0.00316	CcSEcCtD
Crizotinib—Pulmonary embolism—Docetaxel—skin cancer	0.000259	0.00315	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Docetaxel—skin cancer	0.000259	0.00315	CcSEcCtD
Crizotinib—Hypokalaemia—Temozolomide—skin cancer	0.000257	0.00313	CcSEcCtD
Crizotinib—Syncope—Imiquimod—skin cancer	0.000255	0.0031	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000255	0.00309	CcSEcCtD
Crizotinib—Neutropenia—Dactinomycin—skin cancer	0.000253	0.00307	CcSEcCtD
Crizotinib—Loss of consciousness—Imiquimod—skin cancer	0.00025	0.00304	CcSEcCtD
Crizotinib—Muscular weakness—Temozolomide—skin cancer	0.000249	0.00303	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000249	0.00303	CcSEcCtD
Crizotinib—Fluid retention—Docetaxel—skin cancer	0.000246	0.00299	CcSEcCtD
Crizotinib—Neuropathy—Docetaxel—skin cancer	0.000243	0.00296	CcSEcCtD
Crizotinib—Pneumonia—Dactinomycin—skin cancer	0.000242	0.00295	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00024	0.00292	CcSEcCtD
Crizotinib—FER—lymphoid tissue—skin cancer	0.000237	0.00262	CbGeAlD
Crizotinib—RIPK2—epithelium—skin cancer	0.000236	0.00262	CbGeAlD
Crizotinib—Decreased appetite—Vemurafenib—skin cancer	0.000236	0.00287	CcSEcCtD
Crizotinib—MAP3K2—connective tissue—skin cancer	0.000236	0.00261	CbGeAlD
Crizotinib—LYN—lymphoid tissue—skin cancer	0.000236	0.00261	CbGeAlD
Crizotinib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000235	0.00285	CcSEcCtD
Crizotinib—MERTK—mammalian vulva—skin cancer	0.000235	0.0026	CbGeAlD
Crizotinib—Fatigue—Vemurafenib—skin cancer	0.000234	0.00285	CcSEcCtD
Crizotinib—MET—head—skin cancer	0.000234	0.00258	CbGeAlD
Crizotinib—Constipation—Vemurafenib—skin cancer	0.000232	0.00283	CcSEcCtD
Crizotinib—MAP4K1—lymphoid tissue—skin cancer	0.000232	0.00257	CbGeAlD
Crizotinib—Oedema—Imiquimod—skin cancer	0.000232	0.00282	CcSEcCtD
Crizotinib—PTK2—connective tissue—skin cancer	0.000231	0.00256	CbGeAlD
Crizotinib—Hypoaesthesia—Bleomycin—skin cancer	0.000231	0.0028	CcSEcCtD
Crizotinib—Infection—Imiquimod—skin cancer	0.00023	0.0028	CcSEcCtD
Crizotinib—Muscular weakness—Fluorouracil—skin cancer	0.00023	0.00279	CcSEcCtD
Crizotinib—TYK2—connective tissue—skin cancer	0.00023	0.00254	CbGeAlD
Crizotinib—LIMK2—mammalian vulva—skin cancer	0.000229	0.00254	CbGeAlD
Crizotinib—ALK—female reproductive system—skin cancer	0.000229	0.00253	CbGeAlD
Crizotinib—TYRO3—female reproductive system—skin cancer	0.000229	0.00253	CbGeAlD
Crizotinib—FER—female reproductive system—skin cancer	0.000229	0.00253	CbGeAlD
Crizotinib—NUAK2—mammalian vulva—skin cancer	0.000229	0.00253	CbGeAlD
Crizotinib—Neutropenia—Temozolomide—skin cancer	0.000228	0.00278	CcSEcCtD
Crizotinib—Shock—Imiquimod—skin cancer	0.000228	0.00277	CcSEcCtD
Crizotinib—IGF1R—lymphoid tissue—skin cancer	0.000228	0.00252	CbGeAlD
Crizotinib—Nervous system disorder—Imiquimod—skin cancer	0.000227	0.00276	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Temozolomide—skin cancer	0.000227	0.00276	CcSEcCtD
Crizotinib—MAP3K12—mammalian vulva—skin cancer	0.000227	0.00251	CbGeAlD
Crizotinib—ACVR1—mammalian vulva—skin cancer	0.000227	0.00251	CbGeAlD
Crizotinib—CSF1R—nipple—skin cancer	0.000226	0.00251	CbGeAlD
Crizotinib—CDK7—head—skin cancer	0.000226	0.0025	CbGeAlD
Crizotinib—Skin disorder—Imiquimod—skin cancer	0.000225	0.00274	CcSEcCtD
Crizotinib—RIPK2—skin of body—skin cancer	0.000225	0.00249	CbGeAlD
Crizotinib—Sepsis—Docetaxel—skin cancer	0.000225	0.00273	CcSEcCtD
Crizotinib—MAP4K2—lymphoid tissue—skin cancer	0.000225	0.00249	CbGeAlD
Crizotinib—MAP3K19—female reproductive system—skin cancer	0.000224	0.00248	CbGeAlD
Crizotinib—BMPR1B—female reproductive system—skin cancer	0.000224	0.00248	CbGeAlD
Crizotinib—RPS6KB1—connective tissue—skin cancer	0.000222	0.00246	CbGeAlD
Crizotinib—Weight decreased—Temozolomide—skin cancer	0.000221	0.00269	CcSEcCtD
Crizotinib—AXL—connective tissue—skin cancer	0.00022	0.00244	CbGeAlD
Crizotinib—TNK2—female reproductive system—skin cancer	0.00022	0.00243	CbGeAlD
Crizotinib—IGF1R—female reproductive system—skin cancer	0.00022	0.00243	CbGeAlD
Crizotinib—PTK2—epithelium—skin cancer	0.000219	0.00243	CbGeAlD
Crizotinib—Pneumonia—Temozolomide—skin cancer	0.000219	0.00266	CcSEcCtD
Crizotinib—Infestation—Temozolomide—skin cancer	0.000218	0.00265	CcSEcCtD
Crizotinib—Infestation NOS—Temozolomide—skin cancer	0.000218	0.00265	CcSEcCtD
Crizotinib—MAP4K2—female reproductive system—skin cancer	0.000217	0.0024	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000216	0.00263	CcSEcCtD
Crizotinib—AURKA—lymphoid tissue—skin cancer	0.000216	0.00239	CbGeAlD
Crizotinib—EPHA3—head—skin cancer	0.000216	0.00239	CbGeAlD
Crizotinib—ACVR1B—head—skin cancer	0.000216	0.00239	CbGeAlD
Crizotinib—NEK9—lymph node—skin cancer	0.000216	0.00239	CbGeAlD
Crizotinib—Body temperature increased—Vemurafenib—skin cancer	0.000215	0.00261	CcSEcCtD
Crizotinib—TIE1—female reproductive system—skin cancer	0.000214	0.00237	CbGeAlD
Crizotinib—STK3—female reproductive system—skin cancer	0.000214	0.00237	CbGeAlD
Crizotinib—Neuropathy peripheral—Temozolomide—skin cancer	0.000214	0.0026	CcSEcCtD
Crizotinib—RPS6KB1—epithelium—skin cancer	0.000211	0.00234	CbGeAlD
Crizotinib—EPHB4—connective tissue—skin cancer	0.00021	0.00233	CbGeAlD
Crizotinib—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000209	0.00254	CcSEcCtD
Crizotinib—Hepatic failure—Docetaxel—skin cancer	0.000209	0.00254	CcSEcCtD
Crizotinib—JAK2—connective tissue—skin cancer	0.000209	0.00231	CbGeAlD
Crizotinib—PTK2—skin of body—skin cancer	0.000209	0.00231	CbGeAlD
Crizotinib—MERTK—lymphoid tissue—skin cancer	0.000208	0.00231	CbGeAlD
Crizotinib—AURKA—female reproductive system—skin cancer	0.000208	0.00231	CbGeAlD
Crizotinib—Paraesthesia—Imiquimod—skin cancer	0.000208	0.00253	CcSEcCtD
Crizotinib—TYK2—skin of body—skin cancer	0.000207	0.0023	CbGeAlD
Crizotinib—Dyspnoea—Imiquimod—skin cancer	0.000207	0.00251	CcSEcCtD
Crizotinib—TESK1—female reproductive system—skin cancer	0.000207	0.00229	CbGeAlD
Crizotinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000206	0.0025	CcSEcCtD
Crizotinib—JAK3—head—skin cancer	0.000206	0.00228	CbGeAlD
Crizotinib—EPHA6—head—skin cancer	0.000206	0.00228	CbGeAlD
Crizotinib—DCLK1—head—skin cancer	0.000205	0.00227	CbGeAlD
Crizotinib—Dyspepsia—Imiquimod—skin cancer	0.000204	0.00248	CcSEcCtD
Crizotinib—LIMK2—lymphoid tissue—skin cancer	0.000204	0.00226	CbGeAlD
Crizotinib—STK4—head—skin cancer	0.000202	0.00224	CbGeAlD
Crizotinib—Pneumonia—Fluorouracil—skin cancer	0.000202	0.00245	CcSEcCtD
Crizotinib—FLT3—lymphoid tissue—skin cancer	0.000202	0.00223	CbGeAlD
Crizotinib—Decreased appetite—Imiquimod—skin cancer	0.000202	0.00245	CcSEcCtD
Crizotinib—TEK—connective tissue—skin cancer	0.000201	0.00223	CbGeAlD
Crizotinib—Infestation—Fluorouracil—skin cancer	0.000201	0.00244	CcSEcCtD
Crizotinib—Infestation NOS—Fluorouracil—skin cancer	0.000201	0.00244	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.0002	0.00243	CcSEcCtD
Crizotinib—Fatigue—Imiquimod—skin cancer	0.0002	0.00243	CcSEcCtD
Crizotinib—EPHB4—epithelium—skin cancer	0.0002	0.00221	CbGeAlD
Crizotinib—AXL—skin of body—skin cancer	0.000199	0.0022	CbGeAlD
Crizotinib—JAK2—epithelium—skin cancer	0.000198	0.0022	CbGeAlD
Crizotinib—Visual disturbance—Docetaxel—skin cancer	0.000198	0.00241	CcSEcCtD
Crizotinib—EPHA4—mammalian vulva—skin cancer	0.000198	0.00219	CbGeAlD
Crizotinib—Neuropathy peripheral—Fluorouracil—skin cancer	0.000197	0.00239	CcSEcCtD
Crizotinib—PRKD1—lymph node—skin cancer	0.000197	0.00218	CbGeAlD
Crizotinib—LIMK2—female reproductive system—skin cancer	0.000197	0.00218	CbGeAlD
Crizotinib—EPHA2—epithelium—skin cancer	0.000196	0.00217	CbGeAlD
Crizotinib—Asthenia—Vemurafenib—skin cancer	0.000195	0.00237	CcSEcCtD
Crizotinib—Hypoaesthesia—Temozolomide—skin cancer	0.000195	0.00237	CcSEcCtD
Crizotinib—MAP3K12—female reproductive system—skin cancer	0.000194	0.00215	CbGeAlD
Crizotinib—FLT3—female reproductive system—skin cancer	0.000194	0.00215	CbGeAlD
Crizotinib—ACVR1—female reproductive system—skin cancer	0.000194	0.00215	CbGeAlD
Crizotinib—LIMK1—lymph node—skin cancer	0.000194	0.00215	CbGeAlD
Crizotinib—Urinary tract disorder—Temozolomide—skin cancer	0.000193	0.00235	CcSEcCtD
Crizotinib—Oedema peripheral—Temozolomide—skin cancer	0.000193	0.00234	CcSEcCtD
Crizotinib—Urethral disorder—Temozolomide—skin cancer	0.000192	0.00233	CcSEcCtD
Crizotinib—TEK—epithelium—skin cancer	0.000191	0.00212	CbGeAlD
Crizotinib—TYRO3—head—skin cancer	0.000191	0.00211	CbGeAlD
Crizotinib—EPHA5—head—skin cancer	0.000191	0.00211	CbGeAlD
Crizotinib—ALK—head—skin cancer	0.000191	0.00211	CbGeAlD
Crizotinib—FER—head—skin cancer	0.000191	0.00211	CbGeAlD
Crizotinib—STK35—female reproductive system—skin cancer	0.00019	0.00211	CbGeAlD
Crizotinib—TBK1—mammalian vulva—skin cancer	0.00019	0.00211	CbGeAlD
Crizotinib—LYN—head—skin cancer	0.00019	0.0021	CbGeAlD
Crizotinib—TYK2—mammalian vulva—skin cancer	0.000189	0.00209	CbGeAlD
Crizotinib—PRKD3—lymph node—skin cancer	0.000189	0.00209	CbGeAlD
Crizotinib—JAK2—skin of body—skin cancer	0.000189	0.00209	CbGeAlD
Crizotinib—Visual impairment—Temozolomide—skin cancer	0.000188	0.00229	CcSEcCtD
Crizotinib—BMPR1B—head—skin cancer	0.000187	0.00207	CbGeAlD
Crizotinib—MAP3K19—head—skin cancer	0.000187	0.00207	CbGeAlD
Crizotinib—IRAK1—mammalian vulva—skin cancer	0.000187	0.00207	CbGeAlD
Crizotinib—Anaemia—Bleomycin—skin cancer	0.000187	0.00227	CcSEcCtD
Crizotinib—Diarrhoea—Vemurafenib—skin cancer	0.000186	0.00226	CcSEcCtD
Crizotinib—YES1—connective tissue—skin cancer	0.000186	0.00206	CbGeAlD
Crizotinib—DSTYK—lymph node—skin cancer	0.000185	0.00204	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—skin cancer	0.000184	0.00203	CbGeAlD
Crizotinib—TAOK3—connective tissue—skin cancer	0.000184	0.00203	CbGeAlD
Crizotinib—TNK2—head—skin cancer	0.000184	0.00203	CbGeAlD
Crizotinib—IGF1R—head—skin cancer	0.000184	0.00203	CbGeAlD
Crizotinib—BMP2K—female reproductive system—skin cancer	0.000183	0.00203	CbGeAlD
Crizotinib—Body temperature increased—Imiquimod—skin cancer	0.000183	0.00223	CcSEcCtD
Crizotinib—RPS6KB1—mammalian vulva—skin cancer	0.000183	0.00203	CbGeAlD
Crizotinib—Eye disorder—Temozolomide—skin cancer	0.000183	0.00222	CcSEcCtD
Crizotinib—BLK—lymph node—skin cancer	0.000182	0.00202	CbGeAlD
Crizotinib—LCK—mammalian vulva—skin cancer	0.000182	0.00202	CbGeAlD
Crizotinib—FGR—mammalian vulva—skin cancer	0.000182	0.00202	CbGeAlD
Crizotinib—MAP3K3—skin of body—skin cancer	0.000182	0.00201	CbGeAlD
Crizotinib—Cardiac disorder—Temozolomide—skin cancer	0.000181	0.00221	CcSEcCtD
Crizotinib—AXL—mammalian vulva—skin cancer	0.000181	0.00201	CbGeAlD
Crizotinib—Leukopenia—Bleomycin—skin cancer	0.000181	0.0022	CcSEcCtD
Crizotinib—LTK—lymph node—skin cancer	0.00018	0.002	CbGeAlD
Crizotinib—CASK—lymph node—skin cancer	0.00018	0.002	CbGeAlD
Crizotinib—Dizziness—Vemurafenib—skin cancer	0.00018	0.00219	CcSEcCtD
Crizotinib—Hypoaesthesia—Fluorouracil—skin cancer	0.000179	0.00218	CcSEcCtD
Crizotinib—ABL1—nipple—skin cancer	0.000179	0.00198	CbGeAlD
Crizotinib—SRC—connective tissue—skin cancer	0.000179	0.00198	CbGeAlD
Crizotinib—STK3—head—skin cancer	0.000179	0.00198	CbGeAlD
Crizotinib—TIE1—head—skin cancer	0.000179	0.00198	CbGeAlD
Crizotinib—PTK2B—female reproductive system—skin cancer	0.000177	0.00196	CbGeAlD
Crizotinib—Mediastinal disorder—Temozolomide—skin cancer	0.000176	0.00214	CcSEcCtD
Crizotinib—RIPK2—female reproductive system—skin cancer	0.000176	0.00194	CbGeAlD
Crizotinib—MAPK7—lymph node—skin cancer	0.000175	0.00193	CbGeAlD
Crizotinib—TXK—lymph node—skin cancer	0.000175	0.00193	CbGeAlD
Crizotinib—SLK—mammalian vulva—skin cancer	0.000175	0.00193	CbGeAlD
Crizotinib—AURKA—head—skin cancer	0.000174	0.00193	CbGeAlD
Crizotinib—Anaemia—Dactinomycin—skin cancer	0.000174	0.00211	CcSEcCtD
Crizotinib—EPHB6—skin of body—skin cancer	0.000174	0.00192	CbGeAlD
Crizotinib—EPHB4—mammalian vulva—skin cancer	0.000173	0.00192	CbGeAlD
Crizotinib—FES—lymph node—skin cancer	0.000173	0.00191	CbGeAlD
Crizotinib—Vomiting—Vemurafenib—skin cancer	0.000173	0.0021	CcSEcCtD
Crizotinib—MAP3K2—lymphoid tissue—skin cancer	0.000173	0.00191	CbGeAlD
Crizotinib—TESK1—head—skin cancer	0.000173	0.00191	CbGeAlD
Crizotinib—JAK2—mammalian vulva—skin cancer	0.000172	0.0019	CbGeAlD
Crizotinib—Rash—Vemurafenib—skin cancer	0.000171	0.00208	CcSEcCtD
Crizotinib—Dermatitis—Vemurafenib—skin cancer	0.000171	0.00208	CcSEcCtD
Crizotinib—Malnutrition—Temozolomide—skin cancer	0.00017	0.00207	CcSEcCtD
Crizotinib—EPHA2—mammalian vulva—skin cancer	0.00017	0.00188	CbGeAlD
Crizotinib—SRC—epithelium—skin cancer	0.00017	0.00188	CbGeAlD
Crizotinib—EPHA4—female reproductive system—skin cancer	0.00017	0.00188	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000169	0.00206	CcSEcCtD
Crizotinib—TBK1—lymphoid tissue—skin cancer	0.000169	0.00187	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—skin cancer	0.000169	0.00187	CbGeAlD
Crizotinib—Leukopenia—Dactinomycin—skin cancer	0.000168	0.00205	CcSEcCtD
Crizotinib—TYK2—lymphoid tissue—skin cancer	0.000168	0.00186	CbGeAlD
Crizotinib—MERTK—head—skin cancer	0.000168	0.00186	CbGeAlD
Crizotinib—Dysgeusia—Temozolomide—skin cancer	0.000167	0.00203	CcSEcCtD
Crizotinib—MAP3K2—female reproductive system—skin cancer	0.000166	0.00184	CbGeAlD
Crizotinib—Asthenia—Imiquimod—skin cancer	0.000166	0.00202	CcSEcCtD
Crizotinib—MAP4K5—mammalian vulva—skin cancer	0.000166	0.00184	CbGeAlD
Crizotinib—MAP3K3—mammalian vulva—skin cancer	0.000166	0.00184	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000166	0.00202	CcSEcCtD
Crizotinib—Oedema—Bleomycin—skin cancer	0.000165	0.002	CcSEcCtD
Crizotinib—LIMK2—head—skin cancer	0.000164	0.00182	CbGeAlD
Crizotinib—Infection—Bleomycin—skin cancer	0.000164	0.00199	CcSEcCtD
Crizotinib—MET—lymph node—skin cancer	0.000164	0.00181	CbGeAlD
Crizotinib—PTK2—female reproductive system—skin cancer	0.000163	0.0018	CbGeAlD
Crizotinib—TBK1—female reproductive system—skin cancer	0.000163	0.0018	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—skin cancer	0.000163	0.0018	CbGeAlD
Crizotinib—MAP3K12—head—skin cancer	0.000162	0.0018	CbGeAlD
Crizotinib—ACVR1—head—skin cancer	0.000162	0.0018	CbGeAlD
Crizotinib—TYK2—female reproductive system—skin cancer	0.000162	0.00179	CbGeAlD
Crizotinib—FGR—lymphoid tissue—skin cancer	0.000162	0.00179	CbGeAlD
Crizotinib—SRC—skin of body—skin cancer	0.000162	0.00179	CbGeAlD
Crizotinib—Nausea—Vemurafenib—skin cancer	0.000161	0.00196	CcSEcCtD
Crizotinib—AXL—lymphoid tissue—skin cancer	0.000161	0.00178	CbGeAlD
Crizotinib—Arrhythmia—Fluorouracil—skin cancer	0.000161	0.00196	CcSEcCtD
Crizotinib—CSF1R—connective tissue—skin cancer	0.000161	0.00178	CbGeAlD
Crizotinib—Vision blurred—Temozolomide—skin cancer	0.00016	0.00195	CcSEcCtD
Crizotinib—IRAK1—female reproductive system—skin cancer	0.00016	0.00177	CbGeAlD
Crizotinib—STK35—head—skin cancer	0.000159	0.00176	CbGeAlD
Crizotinib—Diarrhoea—Imiquimod—skin cancer	0.000159	0.00193	CcSEcCtD
Crizotinib—EPHB6—mammalian vulva—skin cancer	0.000158	0.00175	CbGeAlD
Crizotinib—CDK7—lymph node—skin cancer	0.000158	0.00175	CbGeAlD
Crizotinib—Anaemia—Temozolomide—skin cancer	0.000157	0.00191	CcSEcCtD
Crizotinib—TAOK2—lymph node—skin cancer	0.000157	0.00174	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—skin cancer	0.000157	0.00174	CbGeAlD
Crizotinib—FGR—female reproductive system—skin cancer	0.000156	0.00173	CbGeAlD
Crizotinib—AXL—female reproductive system—skin cancer	0.000155	0.00172	CbGeAlD
Crizotinib—Oedema—Dactinomycin—skin cancer	0.000154	0.00187	CcSEcCtD
Crizotinib—Dizziness—Imiquimod—skin cancer	0.000153	0.00186	CcSEcCtD
Crizotinib—BMP2K—head—skin cancer	0.000153	0.0017	CbGeAlD
Crizotinib—YES1—mammalian vulva—skin cancer	0.000153	0.0017	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—skin cancer	0.000153	0.00169	CbGeAlD
Crizotinib—Infection—Dactinomycin—skin cancer	0.000153	0.00186	CcSEcCtD
Crizotinib—Leukopenia—Temozolomide—skin cancer	0.000152	0.00185	CcSEcCtD
Crizotinib—Neutropenia—Docetaxel—skin cancer	0.000152	0.00185	CcSEcCtD
Crizotinib—STK10—mammalian vulva—skin cancer	0.000152	0.00168	CbGeAlD
Crizotinib—TAOK3—mammalian vulva—skin cancer	0.000151	0.00167	CbGeAlD
Crizotinib—EPHA3—lymph node—skin cancer	0.000151	0.00167	CbGeAlD
Crizotinib—ACVR1B—lymph node—skin cancer	0.000151	0.00167	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—skin cancer	0.000151	0.00167	CbGeAlD
Crizotinib—EPHB4—female reproductive system—skin cancer	0.000148	0.00164	CbGeAlD
Crizotinib—PTK2B—head—skin cancer	0.000148	0.00164	CbGeAlD
Crizotinib—Paraesthesia—Bleomycin—skin cancer	0.000148	0.0018	CcSEcCtD
Crizotinib—Vision blurred—Fluorouracil—skin cancer	0.000148	0.0018	CcSEcCtD
Crizotinib—Vomiting—Imiquimod—skin cancer	0.000147	0.00179	CcSEcCtD
Crizotinib—JAK2—female reproductive system—skin cancer	0.000147	0.00163	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—skin cancer	0.000147	0.00163	CbGeAlD
Crizotinib—TEK—lymphoid tissue—skin cancer	0.000147	0.00163	CbGeAlD
Crizotinib—Weight decreased—Docetaxel—skin cancer	0.000147	0.00179	CcSEcCtD
Crizotinib—Dyspnoea—Bleomycin—skin cancer	0.000147	0.00179	CcSEcCtD
Crizotinib—RIPK2—head—skin cancer	0.000147	0.00162	CbGeAlD
Crizotinib—Rash—Imiquimod—skin cancer	0.000146	0.00178	CcSEcCtD
Crizotinib—Dermatitis—Imiquimod—skin cancer	0.000146	0.00178	CcSEcCtD
Crizotinib—Pneumonia—Docetaxel—skin cancer	0.000146	0.00177	CcSEcCtD
Crizotinib—EPHA2—female reproductive system—skin cancer	0.000146	0.00161	CbGeAlD
Crizotinib—CSF1R—skin of body—skin cancer	0.000145	0.00161	CbGeAlD
Crizotinib—Anaemia—Fluorouracil—skin cancer	0.000145	0.00176	CcSEcCtD
Crizotinib—Infestation NOS—Docetaxel—skin cancer	0.000145	0.00176	CcSEcCtD
Crizotinib—Infestation—Docetaxel—skin cancer	0.000145	0.00176	CcSEcCtD
Crizotinib—JAK3—lymph node—skin cancer	0.000144	0.0016	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000144	0.00175	CcSEcCtD
Crizotinib—DCLK1—lymph node—skin cancer	0.000143	0.00159	CbGeAlD
Crizotinib—Decreased appetite—Bleomycin—skin cancer	0.000143	0.00174	CcSEcCtD
Crizotinib—PLK4—lymph node—skin cancer	0.000142	0.00158	CbGeAlD
Crizotinib—TEK—female reproductive system—skin cancer	0.000142	0.00157	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—skin cancer	0.000142	0.00157	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—skin cancer	0.000142	0.00157	CbGeAlD
Crizotinib—Neuropathy peripheral—Docetaxel—skin cancer	0.000142	0.00173	CcSEcCtD
Crizotinib—EPHA4—head—skin cancer	0.000142	0.00157	CbGeAlD
Crizotinib—STK4—lymph node—skin cancer	0.000142	0.00157	CbGeAlD
Crizotinib—Leukopenia—Fluorouracil—skin cancer	0.00014	0.00171	CcSEcCtD
Crizotinib—MAP3K2—head—skin cancer	0.000139	0.00154	CbGeAlD
Crizotinib—Oedema—Temozolomide—skin cancer	0.000139	0.00169	CcSEcCtD
Crizotinib—Infection—Temozolomide—skin cancer	0.000138	0.00168	CcSEcCtD
Crizotinib—Nausea—Imiquimod—skin cancer	0.000138	0.00167	CcSEcCtD
Crizotinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000137	0.00167	CcSEcCtD
Crizotinib—Nervous system disorder—Temozolomide—skin cancer	0.000136	0.00166	CcSEcCtD
Crizotinib—TBK1—head—skin cancer	0.000136	0.00151	CbGeAlD
Crizotinib—PTK2—head—skin cancer	0.000136	0.00151	CbGeAlD
Crizotinib—YES1—lymphoid tissue—skin cancer	0.000136	0.00151	CbGeAlD
Crizotinib—TYK2—head—skin cancer	0.000135	0.0015	CbGeAlD
Crizotinib—Skin disorder—Temozolomide—skin cancer	0.000135	0.00164	CcSEcCtD
Crizotinib—STK10—lymphoid tissue—skin cancer	0.000135	0.00149	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—skin cancer	0.000134	0.00149	CbGeAlD
Crizotinib—ALK—lymph node—skin cancer	0.000134	0.00148	CbGeAlD
Crizotinib—FER—lymph node—skin cancer	0.000134	0.00148	CbGeAlD
Crizotinib—Decreased appetite—Dactinomycin—skin cancer	0.000134	0.00162	CcSEcCtD
Crizotinib—Fatigue—Dactinomycin—skin cancer	0.000132	0.00161	CcSEcCtD
Crizotinib—TNK1—lymph node—skin cancer	0.000132	0.00147	CbGeAlD
Crizotinib—CSF1R—mammalian vulva—skin cancer	0.000132	0.00146	CbGeAlD
Crizotinib—YES1—female reproductive system—skin cancer	0.000131	0.00145	CbGeAlD
Crizotinib—MAP4K1—lymph node—skin cancer	0.000131	0.00145	CbGeAlD
Crizotinib—BMPR1B—lymph node—skin cancer	0.000131	0.00145	CbGeAlD
Crizotinib—RPS6KB1—head—skin cancer	0.000131	0.00145	CbGeAlD
Crizotinib—SRC—lymphoid tissue—skin cancer	0.000131	0.00145	CbGeAlD
Crizotinib—FGR—head—skin cancer	0.00013	0.00144	CbGeAlD
Crizotinib—Body temperature increased—Bleomycin—skin cancer	0.00013	0.00158	CcSEcCtD
Crizotinib—STK10—female reproductive system—skin cancer	0.00013	0.00144	CbGeAlD
Crizotinib—AXL—head—skin cancer	0.00013	0.00144	CbGeAlD
Crizotinib—TAOK3—female reproductive system—skin cancer	0.000129	0.00143	CbGeAlD
Crizotinib—Hypoaesthesia—Docetaxel—skin cancer	0.000129	0.00157	CcSEcCtD
Crizotinib—IGF1R—lymph node—skin cancer	0.000129	0.00142	CbGeAlD
Crizotinib—TNK2—lymph node—skin cancer	0.000129	0.00142	CbGeAlD
Crizotinib—Urinary tract disorder—Docetaxel—skin cancer	0.000128	0.00156	CcSEcCtD
Crizotinib—Oedema peripheral—Docetaxel—skin cancer	0.000128	0.00156	CcSEcCtD
Crizotinib—Oedema—Fluorouracil—skin cancer	0.000128	0.00156	CcSEcCtD
Crizotinib—Urethral disorder—Docetaxel—skin cancer	0.000127	0.00155	CcSEcCtD
Crizotinib—Infection—Fluorouracil—skin cancer	0.000127	0.00155	CcSEcCtD
Crizotinib—ABL1—connective tissue—skin cancer	0.000127	0.00141	CbGeAlD
Crizotinib—MAP4K2—lymph node—skin cancer	0.000127	0.0014	CbGeAlD
Crizotinib—SRC—female reproductive system—skin cancer	0.000126	0.0014	CbGeAlD
Crizotinib—Nervous system disorder—Fluorouracil—skin cancer	0.000126	0.00153	CcSEcCtD
Crizotinib—Visual impairment—Docetaxel—skin cancer	0.000125	0.00152	CcSEcCtD
Crizotinib—STK3—lymph node—skin cancer	0.000125	0.00138	CbGeAlD
Crizotinib—TIE1—lymph node—skin cancer	0.000125	0.00138	CbGeAlD
Crizotinib—Paraesthesia—Temozolomide—skin cancer	0.000125	0.00152	CcSEcCtD
Crizotinib—Dyspnoea—Temozolomide—skin cancer	0.000124	0.00151	CcSEcCtD
Crizotinib—JAK2—head—skin cancer	0.000123	0.00136	CbGeAlD
Crizotinib—Dyspepsia—Temozolomide—skin cancer	0.000122	0.00149	CcSEcCtD
Crizotinib—AURKA—lymph node—skin cancer	0.000122	0.00135	CbGeAlD
Crizotinib—EPHA2—head—skin cancer	0.000122	0.00135	CbGeAlD
Crizotinib—Eye disorder—Docetaxel—skin cancer	0.000122	0.00148	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—skin cancer	0.000121	0.00148	CcSEcCtD
Crizotinib—TESK1—lymph node—skin cancer	0.000121	0.00134	CbGeAlD
Crizotinib—Decreased appetite—Temozolomide—skin cancer	0.000121	0.00147	CcSEcCtD
Crizotinib—Cardiac disorder—Docetaxel—skin cancer	0.000121	0.00147	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.00012	0.00146	CcSEcCtD
Crizotinib—Fatigue—Temozolomide—skin cancer	0.00012	0.00146	CcSEcCtD
Crizotinib—Constipation—Temozolomide—skin cancer	0.000119	0.00144	CcSEcCtD
Crizotinib—MAP4K5—head—skin cancer	0.000119	0.00131	CbGeAlD
Crizotinib—MAP3K3—head—skin cancer	0.000119	0.00131	CbGeAlD
Crizotinib—TEK—head—skin cancer	0.000119	0.00131	CbGeAlD
Crizotinib—Asthenia—Bleomycin—skin cancer	0.000118	0.00144	CcSEcCtD
Crizotinib—MERTK—lymph node—skin cancer	0.000118	0.0013	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—skin cancer	0.000117	0.0013	CbGeAlD
Crizotinib—Mediastinal disorder—Docetaxel—skin cancer	0.000117	0.00142	CcSEcCtD
Crizotinib—Arrhythmia—Docetaxel—skin cancer	0.000116	0.00141	CcSEcCtD
Crizotinib—LIMK2—lymph node—skin cancer	0.000115	0.00127	CbGeAlD
Crizotinib—Paraesthesia—Fluorouracil—skin cancer	0.000115	0.0014	CcSEcCtD
Crizotinib—ABL1—skin of body—skin cancer	0.000115	0.00127	CbGeAlD
Crizotinib—NUAK2—lymph node—skin cancer	0.000115	0.00127	CbGeAlD
Crizotinib—Dyspnoea—Fluorouracil—skin cancer	0.000114	0.00139	CcSEcCtD
Crizotinib—FLT3—lymph node—skin cancer	0.000114	0.00126	CbGeAlD
Crizotinib—MAP3K12—lymph node—skin cancer	0.000114	0.00126	CbGeAlD
Crizotinib—ACVR1—lymph node—skin cancer	0.000114	0.00126	CbGeAlD
Crizotinib—EPHB6—head—skin cancer	0.000113	0.00126	CbGeAlD
Crizotinib—CSF1R—female reproductive system—skin cancer	0.000113	0.00125	CbGeAlD
Crizotinib—Malnutrition—Docetaxel—skin cancer	0.000113	0.00138	CcSEcCtD
Crizotinib—Dyspepsia—Fluorouracil—skin cancer	0.000113	0.00137	CcSEcCtD
Crizotinib—STK35—lymph node—skin cancer	0.000111	0.00123	CbGeAlD
Crizotinib—Decreased appetite—Fluorouracil—skin cancer	0.000111	0.00135	CcSEcCtD
Crizotinib—Dysgeusia—Docetaxel—skin cancer	0.000111	0.00135	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000111	0.00134	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—skin cancer	0.00011	0.00134	CcSEcCtD
Crizotinib—Body temperature increased—Temozolomide—skin cancer	0.00011	0.00134	CcSEcCtD
Crizotinib—YES1—head—skin cancer	0.00011	0.00121	CbGeAlD
Crizotinib—ABL2—lymph node—skin cancer	0.000109	0.0012	CbGeAlD
Crizotinib—STK10—head—skin cancer	0.000109	0.0012	CbGeAlD
Crizotinib—TAOK3—head—skin cancer	0.000108	0.0012	CbGeAlD
Crizotinib—BMP2K—lymph node—skin cancer	0.000107	0.00119	CbGeAlD
Crizotinib—SRC—head—skin cancer	0.000105	0.00117	CbGeAlD
Crizotinib—Diarrhoea—Dactinomycin—skin cancer	0.000105	0.00128	CcSEcCtD
Crizotinib—Vomiting—Bleomycin—skin cancer	0.000105	0.00127	CcSEcCtD
Crizotinib—Anaemia—Docetaxel—skin cancer	0.000105	0.00127	CcSEcCtD
Crizotinib—ABL1—mammalian vulva—skin cancer	0.000105	0.00116	CbGeAlD
Crizotinib—Rash—Bleomycin—skin cancer	0.000104	0.00126	CcSEcCtD
Crizotinib—Dermatitis—Bleomycin—skin cancer	0.000104	0.00126	CcSEcCtD
Crizotinib—PTK2B—lymph node—skin cancer	0.000104	0.00115	CbGeAlD
Crizotinib—RIPK2—lymph node—skin cancer	0.000103	0.00114	CbGeAlD
Crizotinib—Syncope—Docetaxel—skin cancer	0.000102	0.00123	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—skin cancer	0.000101	0.00123	CcSEcCtD
Crizotinib—Body temperature increased—Fluorouracil—skin cancer	0.000101	0.00123	CcSEcCtD
Crizotinib—Asthenia—Temozolomide—skin cancer	9.97e-05	0.00121	CcSEcCtD
Crizotinib—Loss of consciousness—Docetaxel—skin cancer	9.95e-05	0.00121	CcSEcCtD
Crizotinib—EPHA4—lymph node—skin cancer	9.93e-05	0.0011	CbGeAlD
Crizotinib—Nausea—Bleomycin—skin cancer	9.78e-05	0.00119	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—skin cancer	9.77e-05	0.00119	CcSEcCtD
Crizotinib—MAP3K2—lymph node—skin cancer	9.74e-05	0.00108	CbGeAlD
Crizotinib—Rash—Dactinomycin—skin cancer	9.68e-05	0.00118	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	9.57e-05	0.00116	CcSEcCtD
Crizotinib—PTK2—lymph node—skin cancer	9.54e-05	0.00106	CbGeAlD
Crizotinib—TBK1—lymph node—skin cancer	9.54e-05	0.00106	CbGeAlD
Crizotinib—Diarrhoea—Temozolomide—skin cancer	9.5e-05	0.00116	CcSEcCtD
Crizotinib—TYK2—lymph node—skin cancer	9.47e-05	0.00105	CbGeAlD
Crizotinib—CSF1R—head—skin cancer	9.46e-05	0.00105	CbGeAlD
Crizotinib—IRAK1—lymph node—skin cancer	9.35e-05	0.00104	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—skin cancer	9.28e-05	0.00103	CbGeAlD
Crizotinib—Oedema—Docetaxel—skin cancer	9.24e-05	0.00112	CcSEcCtD
Crizotinib—Dizziness—Temozolomide—skin cancer	9.19e-05	0.00112	CcSEcCtD
Crizotinib—Infection—Docetaxel—skin cancer	9.18e-05	0.00112	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—skin cancer	9.18e-05	0.00102	CbGeAlD
Crizotinib—Nausea—Dactinomycin—skin cancer	9.12e-05	0.00111	CcSEcCtD
Crizotinib—LCK—lymph node—skin cancer	9.12e-05	0.00101	CbGeAlD
Crizotinib—FGR—lymph node—skin cancer	9.12e-05	0.00101	CbGeAlD
Crizotinib—Shock—Docetaxel—skin cancer	9.09e-05	0.00111	CcSEcCtD
Crizotinib—AXL—lymph node—skin cancer	9.08e-05	0.00101	CbGeAlD
Crizotinib—Nervous system disorder—Docetaxel—skin cancer	9.06e-05	0.0011	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—skin cancer	8.97e-05	0.00109	CcSEcCtD
Crizotinib—ABL1—female reproductive system—skin cancer	8.95e-05	0.000991	CbGeAlD
Crizotinib—Vomiting—Temozolomide—skin cancer	8.83e-05	0.00107	CcSEcCtD
Crizotinib—Rash—Temozolomide—skin cancer	8.76e-05	0.00107	CcSEcCtD
Crizotinib—Diarrhoea—Fluorouracil—skin cancer	8.76e-05	0.00106	CcSEcCtD
Crizotinib—Dermatitis—Temozolomide—skin cancer	8.75e-05	0.00106	CcSEcCtD
Crizotinib—SLK—lymph node—skin cancer	8.74e-05	0.000968	CbGeAlD
Crizotinib—EPHB4—lymph node—skin cancer	8.68e-05	0.000961	CbGeAlD
Crizotinib—JAK2—lymph node—skin cancer	8.62e-05	0.000954	CbGeAlD
Crizotinib—EPHA2—lymph node—skin cancer	8.52e-05	0.000943	CbGeAlD
Crizotinib—Dizziness—Fluorouracil—skin cancer	8.46e-05	0.00103	CcSEcCtD
Crizotinib—MAP3K3—lymph node—skin cancer	8.31e-05	0.00092	CbGeAlD
Crizotinib—TEK—lymph node—skin cancer	8.31e-05	0.00092	CbGeAlD
Crizotinib—MAP4K5—lymph node—skin cancer	8.31e-05	0.00092	CbGeAlD
Crizotinib—Paraesthesia—Docetaxel—skin cancer	8.3e-05	0.00101	CcSEcCtD
Crizotinib—Nausea—Temozolomide—skin cancer	8.25e-05	0.001	CcSEcCtD
Crizotinib—Dyspnoea—Docetaxel—skin cancer	8.24e-05	0.001	CcSEcCtD
Crizotinib—Vomiting—Fluorouracil—skin cancer	8.14e-05	0.00099	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—skin cancer	8.13e-05	0.000989	CcSEcCtD
Crizotinib—Rash—Fluorouracil—skin cancer	8.07e-05	0.000981	CcSEcCtD
Crizotinib—Dermatitis—Fluorouracil—skin cancer	8.06e-05	0.00098	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—skin cancer	8.03e-05	0.000976	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—skin cancer	7.98e-05	0.00097	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—skin cancer	7.96e-05	0.000968	CcSEcCtD
Crizotinib—EPHB6—lymph node—skin cancer	7.94e-05	0.000879	CbGeAlD
Crizotinib—Constipation—Docetaxel—skin cancer	7.9e-05	0.000961	CcSEcCtD
Crizotinib—ABCB1—blood vessel—skin cancer	7.7e-05	0.000852	CbGeAlD
Crizotinib—YES1—lymph node—skin cancer	7.67e-05	0.000849	CbGeAlD
Crizotinib—STK10—lymph node—skin cancer	7.6e-05	0.000842	CbGeAlD
Crizotinib—Nausea—Fluorouracil—skin cancer	7.6e-05	0.000924	CcSEcCtD
Crizotinib—TAOK3—lymph node—skin cancer	7.57e-05	0.000838	CbGeAlD
Crizotinib—ABL1—head—skin cancer	7.48e-05	0.000828	CbGeAlD
Crizotinib—SRC—lymph node—skin cancer	7.38e-05	0.000817	CbGeAlD
Crizotinib—Body temperature increased—Docetaxel—skin cancer	7.3e-05	0.000888	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—skin cancer	6.63e-05	0.000806	CcSEcCtD
Crizotinib—CSF1R—lymph node—skin cancer	6.63e-05	0.000734	CbGeAlD
Crizotinib—Diarrhoea—Docetaxel—skin cancer	6.32e-05	0.000769	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—skin cancer	6.11e-05	0.000743	CcSEcCtD
Crizotinib—Vomiting—Docetaxel—skin cancer	5.87e-05	0.000714	CcSEcCtD
Crizotinib—Rash—Docetaxel—skin cancer	5.82e-05	0.000708	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—skin cancer	5.82e-05	0.000708	CcSEcCtD
Crizotinib—Nausea—Docetaxel—skin cancer	5.49e-05	0.000667	CcSEcCtD
Crizotinib—ABL1—lymph node—skin cancer	5.24e-05	0.00058	CbGeAlD
Crizotinib—CYP3A4—female reproductive system—skin cancer	3.93e-05	0.000435	CbGeAlD
Crizotinib—ABCB1—epithelium—skin cancer	3.75e-05	0.000415	CbGeAlD
Crizotinib—ABCB1—mammalian vulva—skin cancer	3.25e-05	0.00036	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—skin cancer	2.89e-05	0.00032	CbGeAlD
Crizotinib—ABCB1—female reproductive system—skin cancer	2.78e-05	0.000308	CbGeAlD
Crizotinib—ABCB1—head—skin cancer	2.33e-05	0.000257	CbGeAlD
Crizotinib—ABCB1—lymph node—skin cancer	1.63e-05	0.00018	CbGeAlD
Crizotinib—LCK—Hemostasis—NRAS—skin cancer	3.41e-06	3.3e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—HRAS—skin cancer	3.4e-06	3.29e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—HRAS—skin cancer	3.39e-06	3.27e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL6—skin cancer	3.36e-06	3.25e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.35e-06	3.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—KRAS—skin cancer	3.35e-06	3.24e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—IL6—skin cancer	3.34e-06	3.23e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—IL6—skin cancer	3.34e-06	3.23e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TERT—skin cancer	3.32e-06	3.21e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HRAS—skin cancer	3.29e-06	3.18e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—skin cancer	3.29e-06	3.18e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—KRAS—skin cancer	3.27e-06	3.16e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—KRAS—skin cancer	3.26e-06	3.15e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—skin cancer	3.25e-06	3.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—skin cancer	3.24e-06	3.13e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—KRAS—skin cancer	3.23e-06	3.12e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—KRAS—skin cancer	3.21e-06	3.1e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—skin cancer	3.21e-06	3.1e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—KRAS—skin cancer	3.21e-06	3.1e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTGS2—skin cancer	3.2e-06	3.09e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KRAS—skin cancer	3.2e-06	3.09e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—skin cancer	3.19e-06	3.08e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—skin cancer	3.17e-06	3.06e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—HRAS—skin cancer	3.16e-06	3.05e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—KRAS—skin cancer	3.15e-06	3.05e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—skin cancer	3.15e-06	3.05e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ERCC2—skin cancer	3.14e-06	3.03e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—KRAS—skin cancer	3.13e-06	3.03e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—KRAS—skin cancer	3.12e-06	3.02e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HRAS—skin cancer	3.11e-06	3e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—HRAS—skin cancer	3.11e-06	3e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—KRAS—skin cancer	3.1e-06	3e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—HRAS—skin cancer	3.09e-06	2.99e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FOXO4—skin cancer	3.08e-06	2.98e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—NRAS—skin cancer	3.08e-06	2.98e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—NRAS—skin cancer	3.07e-06	2.97e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HRAS—skin cancer	3.07e-06	2.97e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—BRAF—skin cancer	3.05e-06	2.95e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—HRAS—skin cancer	3.05e-06	2.94e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—HRAS—skin cancer	3.03e-06	2.93e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—skin cancer	3.02e-06	2.92e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NRAS—skin cancer	3.02e-06	2.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—KRAS—skin cancer	3.02e-06	2.92e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—BRAF—skin cancer	3.01e-06	2.91e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLIN2—skin cancer	3.01e-06	2.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—BRAF—skin cancer	3e-06	2.9e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.98e-06	2.88e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—skin cancer	2.98e-06	2.88e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—skin cancer	2.97e-06	2.87e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—skin cancer	2.97e-06	2.87e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—NRAS—skin cancer	2.97e-06	2.87e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—skin cancer	2.96e-06	2.86e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—NRAS—skin cancer	2.95e-06	2.85e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—NRAS—skin cancer	2.95e-06	2.85e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—skin cancer	2.94e-06	2.84e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TERT—skin cancer	2.94e-06	2.84e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—KRAS—skin cancer	2.94e-06	2.84e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—NRAS—skin cancer	2.93e-06	2.83e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—HRAS—skin cancer	2.91e-06	2.81e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—skin cancer	2.9e-06	2.81e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—BRAF—skin cancer	2.86e-06	2.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—HRAS—skin cancer	2.85e-06	2.76e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—skin cancer	2.84e-06	2.75e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TERT—skin cancer	2.84e-06	2.74e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—skin cancer	2.78e-06	2.69e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—skin cancer	2.78e-06	2.69e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NRAS—skin cancer	2.78e-06	2.68e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—BRAF—skin cancer	2.77e-06	2.68e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—skin cancer	2.77e-06	2.68e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NRAS—skin cancer	2.74e-06	2.65e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—skin cancer	2.74e-06	2.65e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—skin cancer	2.73e-06	2.64e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—skin cancer	2.73e-06	2.64e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NRAS—skin cancer	2.72e-06	2.63e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—skin cancer	2.72e-06	2.63e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NRAS—skin cancer	2.7e-06	2.61e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—skin cancer	2.68e-06	2.59e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO2—skin cancer	2.67e-06	2.59e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—skin cancer	2.66e-06	2.57e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—skin cancer	2.66e-06	2.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TERT—skin cancer	2.65e-06	2.57e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—skin cancer	2.65e-06	2.57e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—KRAS—skin cancer	2.65e-06	2.56e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—skin cancer	2.65e-06	2.56e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KRAS—skin cancer	2.64e-06	2.56e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—skin cancer	2.63e-06	2.55e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—BRAF—skin cancer	2.63e-06	2.54e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—skin cancer	2.63e-06	2.54e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—skin cancer	2.61e-06	2.53e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NRAS—skin cancer	2.61e-06	2.53e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—skin cancer	2.61e-06	2.52e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—skin cancer	2.61e-06	2.52e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—skin cancer	2.6e-06	2.51e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—KRAS—skin cancer	2.6e-06	2.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—skin cancer	2.57e-06	2.48e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—skin cancer	2.56e-06	2.48e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KRAS—skin cancer	2.56e-06	2.47e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—skin cancer	2.55e-06	2.46e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—skin cancer	2.54e-06	2.46e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—KRAS—skin cancer	2.54e-06	2.46e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KRAS—skin cancer	2.54e-06	2.46e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KRAS—skin cancer	2.52e-06	2.44e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—skin cancer	2.5e-06	2.41e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—skin cancer	2.49e-06	2.41e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—skin cancer	2.46e-06	2.37e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—skin cancer	2.45e-06	2.37e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—skin cancer	2.42e-06	2.34e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CSPG4—skin cancer	2.42e-06	2.34e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—skin cancer	2.41e-06	2.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KRAS—skin cancer	2.39e-06	2.31e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KRAS—skin cancer	2.36e-06	2.28e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KRAS—skin cancer	2.34e-06	2.26e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—BRAF—skin cancer	2.33e-06	2.25e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TERT—skin cancer	2.33e-06	2.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KRAS—skin cancer	2.32e-06	2.24e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—skin cancer	2.31e-06	2.23e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—skin cancer	2.31e-06	2.23e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—skin cancer	2.25e-06	2.18e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KRAS—skin cancer	2.25e-06	2.17e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—skin cancer	2.25e-06	2.17e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—BRAF—skin cancer	2.25e-06	2.17e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—skin cancer	2.24e-06	2.16e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—skin cancer	2.24e-06	2.16e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—skin cancer	2.21e-06	2.14e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—skin cancer	2.18e-06	2.11e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—skin cancer	2.17e-06	2.1e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—skin cancer	2.17e-06	2.1e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—skin cancer	2.16e-06	2.09e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—skin cancer	2.16e-06	2.09e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—skin cancer	2.16e-06	2.08e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—skin cancer	2.15e-06	2.08e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—skin cancer	2.14e-06	2.07e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—skin cancer	2.14e-06	2.07e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—skin cancer	2.12e-06	2.05e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—skin cancer	2.11e-06	2.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—BRAF—skin cancer	2.1e-06	2.03e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—skin cancer	2.1e-06	2.03e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—skin cancer	2.08e-06	2.01e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—skin cancer	2.08e-06	2.01e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—skin cancer	2.07e-06	2e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ERCC2—skin cancer	2.06e-06	1.99e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TERT—skin cancer	2.06e-06	1.99e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—skin cancer	2.05e-06	1.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—skin cancer	2.04e-06	1.98e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—skin cancer	2.03e-06	1.96e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—skin cancer	2.01e-06	1.94e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—skin cancer	1.99e-06	1.92e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—skin cancer	1.99e-06	1.92e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—skin cancer	1.97e-06	1.91e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—skin cancer	1.94e-06	1.88e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—skin cancer	1.93e-06	1.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—skin cancer	1.92e-06	1.86e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—skin cancer	1.92e-06	1.86e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—skin cancer	1.92e-06	1.86e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—skin cancer	1.91e-06	1.85e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—skin cancer	1.9e-06	1.84e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—skin cancer	1.89e-06	1.83e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—skin cancer	1.89e-06	1.83e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—skin cancer	1.89e-06	1.82e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—skin cancer	1.88e-06	1.82e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—skin cancer	1.88e-06	1.82e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—skin cancer	1.87e-06	1.81e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—skin cancer	1.87e-06	1.81e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—skin cancer	1.84e-06	1.78e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BRAF—skin cancer	1.84e-06	1.78e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—skin cancer	1.82e-06	1.76e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—skin cancer	1.8e-06	1.74e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—skin cancer	1.79e-06	1.73e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—skin cancer	1.79e-06	1.73e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—skin cancer	1.77e-06	1.71e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—skin cancer	1.76e-06	1.71e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—skin cancer	1.76e-06	1.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—skin cancer	1.74e-06	1.69e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—skin cancer	1.74e-06	1.69e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—skin cancer	1.71e-06	1.66e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—skin cancer	1.71e-06	1.65e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—skin cancer	1.69e-06	1.63e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—skin cancer	1.69e-06	1.63e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—skin cancer	1.65e-06	1.6e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—skin cancer	1.65e-06	1.6e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO2—skin cancer	1.65e-06	1.59e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—skin cancer	1.64e-06	1.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—skin cancer	1.64e-06	1.58e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—skin cancer	1.63e-06	1.58e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—skin cancer	1.63e-06	1.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—skin cancer	1.62e-06	1.57e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—skin cancer	1.62e-06	1.56e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—skin cancer	1.6e-06	1.54e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—skin cancer	1.59e-06	1.54e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—skin cancer	1.58e-06	1.53e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—skin cancer	1.57e-06	1.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—skin cancer	1.57e-06	1.51e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—skin cancer	1.55e-06	1.5e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—skin cancer	1.55e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—skin cancer	1.54e-06	1.49e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—skin cancer	1.53e-06	1.48e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—skin cancer	1.52e-06	1.47e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—skin cancer	1.5e-06	1.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—skin cancer	1.49e-06	1.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—skin cancer	1.47e-06	1.42e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—skin cancer	1.46e-06	1.41e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—skin cancer	1.45e-06	1.4e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—skin cancer	1.43e-06	1.38e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—skin cancer	1.42e-06	1.37e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—skin cancer	1.41e-06	1.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—skin cancer	1.4e-06	1.36e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—skin cancer	1.39e-06	1.34e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—skin cancer	1.38e-06	1.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—skin cancer	1.37e-06	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—skin cancer	1.36e-06	1.32e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—skin cancer	1.34e-06	1.3e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—skin cancer	1.33e-06	1.29e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—skin cancer	1.33e-06	1.28e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—skin cancer	1.32e-06	1.28e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—skin cancer	1.32e-06	1.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—skin cancer	1.31e-06	1.27e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—skin cancer	1.31e-06	1.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—skin cancer	1.28e-06	1.23e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—skin cancer	1.26e-06	1.22e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—skin cancer	1.26e-06	1.22e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—skin cancer	1.25e-06	1.21e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—skin cancer	1.23e-06	1.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—skin cancer	1.22e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—skin cancer	1.22e-06	1.17e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—skin cancer	1.21e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—skin cancer	1.16e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—skin cancer	1.16e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—skin cancer	1.16e-06	1.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—skin cancer	1.14e-06	1.1e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—skin cancer	1.11e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—skin cancer	1.08e-06	1.04e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—skin cancer	1.07e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—skin cancer	1.03e-06	9.98e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—skin cancer	1.02e-06	9.9e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—skin cancer	1.02e-06	9.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—skin cancer	1.01e-06	9.77e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—skin cancer	9.96e-07	9.63e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—skin cancer	9.89e-07	9.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—skin cancer	9.67e-07	9.34e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—skin cancer	9.57e-07	9.25e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—skin cancer	9.32e-07	9.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—skin cancer	9.25e-07	8.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—skin cancer	8.85e-07	8.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—skin cancer	8.82e-07	8.52e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—skin cancer	8.47e-07	8.18e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—skin cancer	8.1e-07	7.83e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—skin cancer	7.84e-07	7.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—skin cancer	7.49e-07	7.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—skin cancer	7.17e-07	6.93e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—skin cancer	5.74e-07	5.55e-06	CbGpPWpGaD
